Much has been learned about the pathogenesis of type 2 diabetes and important new treatments have been generated; however, the prevalence of type 2 diabetes is increasing dramatically. That is why ZonMw, the Dutch Diabetes Research Foundation, Health~Holland and Canadian Institutes of Health Research (CIHR) launched the call Netherlands-Canada Type 2 Diabetes Research Consortium together.
21 november 2019
19 mei 2020,
Wilt u indienen? De volledige subsidieoproep kunt u via onderstaande link bekijken. Hierin staat alle specifieke informatie over deze oproep.
The application procedure consists of two steps:
Pre-Proposal (only to CIHR)
- The closing date for submitting the grant Pre-Proposal to CIHR via ResearchNet is 25 February 2020 at 20:00 (EST). Failure to submit a valid registration to CIHR by the deadline will invalidate both submissions.
Application (ZonMw and CIHR)
Applications submitted to only one funding agency will not be accepted.
ZonMw, the Dutch Diabetes Research Foundation, Health~Holland and CIHR encourage researchers, for-profit private parties and other private parties to apply for a grant for international and interdisciplinary research that will contribute to the battle against type 2 diabetes. The aim of this call is to accelerate research and development to improve the lives of people with type 2 diabetes in Canada and the Netherlands by supporting one (1) internationally competitive and innovative Netherlands-Canada Type 2 Diabetes Research Consortium.
This partnership is intended to fund one Netherlands-Canada Type 2 Diabetes Research Consortium over five years. The Dutch side of the Consortium will be co-funded by three partners (ZonMw, Dutch Diabetes Research Foundation and Health~Holland) for a total investment of € 2.59 M ($3.72M CAD). For this part co-financing is compulsory and must be arranged before the proposal is submitted.
The Canadian side of the consortium will be funded by the CIHR Institute of Nutrition, Metabolism and Diabetes (INMD) with a commitment of €1.39M ($2M CAD) over five years.
The approved Diabetes Research Consortium must start on 1 January 2021.
The Consortium will require a Dutch lead Nominated Principal Applicant and a Canadian lead NPA who will equally share leadership and management of the Consortium. The Dutch side of the Consortium must be comprised of at least four project leaders of the Diabetes II Breakthrough Projects, one of which will be the Netherlands lead (NPA). New co-applicants from the Netherlands, not currently funded through the Breakthrough Projects funding opportunity, will also be allowed to join the Consortium. One Canadian NPA will lead the Canadian side of the Consortium and may be joined by up to four co-applicants from Canada.
An applicant can participate in a maximum of two applications.
The Consortium consists of at least one for-profit enterprise. Foreign for-profit private parties and research organisations are also encouraged to participate in the Consortium, as long as the results of the research project benefit the Dutch knowledge infrastructure and economy.
Please contact us with any questions that are not covered in the FAQs. For general queries, please contact via e-mail email@example.com or by phone.
If you have any technical questions about ProjectNet please contact the service desk.